<DOC>
	<DOC>NCT01944969</DOC>
	<brief_summary>To evaluate the long-term safety and tolerability of brexpiprazole as adjunctive treatment in patients with Major Depressive Disorder (MDD)</brief_summary>
	<brief_title>Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder</brief_title>
	<detailed_description>This extension safety study was terminated early because one of the lead-in studies (14571A) in elderly was terminated and because the Sponsor considered that sufficient long-term safety data has already been collected in the development programme in the population aged 18-65 yrs.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Brexpiprazole</mesh_term>
	<criteria>The patient is judged to benefit from adjunctive treatment with brexpiprazole according to the clinical opinion of the investigator. The patient had MDD at entry in leadin brexpiprazole studies, NCT01838681 / 14570A or NCT01837797 / 14571A, diagnosed according to DSMIVTRâ„¢. The patient agrees to protocoldefined use of effective contraception. The patient has a disease or takes medication that could, in the investigator's opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study. The patient has been diagnosed with a psychiatric disorder other than MDD during the leadin studies NCT01838681 / 14570A or NCT01837797 / 14571A. The patient, in the opinion of the investigator or according to CSSRS, is at significant risk of suicide. The patient has any relevant medical history or current presence of systemic disease. The patient has, at the Baseline Visit an abnormal ECG that is, in the investigator's opinion, clinically significant. The patient has a moderate or severe ongoing adverse event related to study medication from the leadin studies considered of potential safety risk by the investigator. The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason. Other inclusion and exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>